Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · IEX Real-Time Price · USD
50.31
-3.44 (-6.40%)
May 17, 2024, 4:00 PM EDT - Market closed
Apogee Therapeutics Employees
Apogee Therapeutics had 9 employees on March 1, 2024. The number of employees decreased by 16 or -64.00% since the number was reported on June 22, 2023.
Employees
9
Change
-16
Growth
-64.00%
Revenue / Employee
n/a
Profits / Employee
-$11,506,000
Market Cap
2.95B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 1, 2024 | 9 | -16 | -64.00% |
| Jun 22, 2023 | 25 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| QuidelOrtho | 7,100 |
| Neogen | 2,640 |
| Tandem Diabetes Care | 2,400 |
| iRhythm Technologies | 2,000 |
| 10x Genomics | 1,259 |
| Olink Holding AB (publ) | 707 |
| Iovance Biotherapeutics | 557 |
| Denali Therapeutics | 445 |
APGE News
- 3 days ago - Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases - GlobeNewsWire
- 5 days ago - Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 12 days ago - Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases - GlobeNewsWire
- 2 months ago - Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million - GlobeNewsWire
- 2 months ago - Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire